

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



ATTORNEYS AT LAW

SUITE 600

1100 NEW YORK AVENUE, N.W.  
WASHINGTON, D.C. 20005-3934

(202) 371-2600

FACSIMILE (202) 371-2540, (202) 371-6566

ROBERT GREENE STERNE  
EDWARD J. KESSLER  
JORGE A. GOLDSTEIN  
SAMUEL L. FOX  
DAVID K.S. CORNWELL  
ROBERT W. ESMOND  
TRACY-GENE G. DURKIN  
MICHELE A. CIMBALA  
MICHAEL B. RAY  
ROBERT E. SOKOHL  
ERIC K. STEFFE  
MICHAEL Q. LEE

JOHN M. COVERT\*  
LINDA E. ALCORN  
RAZ E. FLESHNER  
ROBERT C. MILLONIG  
STEVEN R. LUDWIG  
MICHAEL V. MESSINGER  
JUDITH U. KIM  
KEITH KIND  
TIMOTHY J. SHEA, JR.  
DONALD R. MCPHAIL  
PATRICK E. GARRETT  
BARBARA A. PARVIS  
MICHAEL A. RAHMAN\*

STEPHEN G. WHITESIDE\*  
NOEL B. WHITLEY\*  
JEFFREY T. HELVEY\*  
RICHARD A. DUNNING, JR.  
KIMBERLIN L. MORLEY  
RALPH P. ALBRECHT  
HEIDI L. KRAUS\*  
JEFFREY R. KURIN\*  
CARL B. MASSEY, JR.\*  
RAYMOND M. LIEN\*  
PATRICK D. O'BRIEN\*  
BRIAN S. ROSENBLUM\*

DONALD J. FEATHERSTONE\*\*  
LAWRENCE B. BUGAISKY\*\*  
KAREN R. MARKOWICZ\*\*  
GRANT E. REED\*\*  
VICTOR E. JOHNSON\*\*  
SERGE SIRA\*\*

\*BAR OTHER THAN D.C.  
\*\*REGISTERED PATENT AGENTS

WRITER'S DIRECT NUMBER

(202) 371-2609  
INTERNET ADDRESS

JGOID@SKGF.COM

July 27, 1998

Assistant Commissioner for Patents  
Washington, D.C. 20231

Re: U.S. Utility Patent Application  
Appl. No. 09/065,902; Filed: April 24, 1998

For: **Purified 20 kDa Presenilin 2 C-terminal Fragment  
and Methods of Screening for Compounds That  
Inhibit Proteolysis of Presenilin 2**

Inventors: Tanzi and Kim

Our Ref: 0609.4270001/JAG/S-S

JUL 29 1998  
GROUP 1800

Sir:

Transmitted herewith for appropriate action are the following documents:

1. Information Disclosure Statement (*in duplicate*);
2. Form PTO 1449 (21 pages) citing 61 references;
3. Sixty-one (61) references (AR1-AT1, AR2-AT2, AR3-AT3, AR4-AT4, AR5-AT5, AR6-AT6, AR7-AT7, AR8-AT8, AR9-AT9, AR10-AT10, AR11-AT11, AR12-AT12, AR13-AT13, AR14-AT14, AR15-AT15, AR16-AT16, AR17-AT17, AR18-AT18, AR19-AT19, AR20-AT20, and AR21); and

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Assistant Commissioner for Patents  
July 27, 1998  
Page 2


4. One (1) return postcard.

It is respectfully requested that the attached postcard be stamped with the date of filing of these documents, and that it be returned to our courier. In the event that extensions of time are necessary to prevent abandonment of this patent application, then such extensions of time are hereby petitioned.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036. A duplicate copy of this letter is enclosed.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Jorge A. Goldstein  
Attorney for Applicants  
Registration No. 29.021

JAG:S-S:aye  
Enclosures

P. USERS AELLIS SSIRA 0609 427-1 427-1 tm3  
SKGF Rev 1 25 98 dew

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

TANZI and KIM

Appl. No. 09/065,902

Filed: April 24, 1998

For: **Purified 20 kDa Presenilin 2 C-terminal Fragment and Methods of Screening for Compounds that Inhibit Proteolysis of Presenilin 2**

JUL 29 1998

Art Unit: 1643

GROUP 1800

Examiner: To be assigned

Atty. Docket: 0609.4270001/JAG/S-S



**Information Disclosure Statement**

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

Listed on accompanying Form PTO-1449 (twenty-one pages) are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. A copy of each of these documents is provided.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith. It is further understood that the Examiner will consider information that had been cited or submitted to the U.S. Patent and Trademark Office in a prior application relied on under 35 U.S.C. § 120. 1138 OG 37, 38 (May 19, 1992).


This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No statement or fee is required.

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and to indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,

STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

  
Jorge A. Goldstein  
Attorney for Applicants  
Registration No. 29,021

Date: 7/27/98

1100 New York Avenue, N.W.  
Suite 600  
Washington, D.C. 20005-3934  
(202) 371-2600